No Prescription |
 |
 | ||
|
Prescription Drugs 11 |
|
| ||
No Prescription » Prescription Drugs 11
Micardis Plus Generic Telmisartan Hydrochlorothiazide Microgynon Generic Levonorgestrel Ethhinylestradiol Mikostatin oral suspension Mycostatin Minirin Melt Generic Desmopressin Moduretic Generic Amiloride Hydrochlorothiazide Momecon cream Generic Mometasone Furoate Monodur Generic Isosorbide 5 mononitrate NEO MERCAZOLE Generic Carbimazole Nicolet Fresh Mint Chewing Gum Nicorette Gum Nicorette Gum Generic Nicotine Gum Nicorette inhaler Generic Nicotine Inhaler Nicorette Nasal spray Generic Nicotine Nasal Spray Nicotinell Fruit Generic Nicotine Nicotinell Mint Generic Nicotine Nicotinell TTS 10 Generic Nicotine Nicotinell TTS 20 Generic Nicotine Nicotinell TTS 30 Generic Nicotine Nifedipine XR Generic Procardia
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|